Baloncibart Phase 2 Trial Shows Reduced Orthostatic Heart Rate
The POTS Phase 2 trial reported reduced orthostatic heart rate and improved orthostatic symptoms with baloncibart, an NPR1-blocking antibody.
Story updates
10:00:42 PM UTC
SquawkNews
REGENERON PHARMACEUTICALS - PLANS PHASE 3 TRIAL FOR BALONCIBART IN FIRST HALF OF 2027
10:02:13 PM UTC
SquawkNews
Regeneron reported that baloncibart 450 mg reduced standing heart-rate change versus placebo by 11.4 bpm at day 8 and 7.4 bpm at day 29; no formal hypothesis testing was prespecified. A Phase 3 trial is planned for the first half of 2027.Material DetailsContext by AI AnalystThis is an early clinica…
10:04:47 PM UTC
SquawkNews
In the randomized Phase 2 PINNACLE trial, a single 450 mg subcutaneous dose reduced DeltaHR vs. plac